Genfit S.A.

OTCPK:GNFT.Y Stok Raporu

Piyasa değeri: US$541.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genfit Yönetim

Yönetim kriter kontrolleri 3/4

Genfit CEO'su M. Prigent, Sep2019 tarihinde atandı, in görev süresi 6.5 yıldır. in toplam yıllık tazminatı € 681.95K olup, şirket hissesi ve opsiyonları dahil olmak üzere 59.5% maaş ve 40.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.062% ine doğrudan sahiptir ve bu hisseler $ 333.78K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4 yıl ve 8.8 yıldır.

Anahtar bilgiler

M. Prigent

İcra Kurulu Başkanı

€681.9k

Toplam tazminat

CEO maaş yüzdesi59.47%
CEO görev süresi6.5yrs
CEO sahipliği0.06%
Yönetim ortalama görev süresi4yrs
Yönetim Kurulu ortalama görev süresi8.8yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Nov 21

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Summary Genfit's Iqirvo received FDA approval in June 2024 for treating primary biliary cholangitis. Gilead's Livdelzi has shown superior efficacy in reducing alkaline phosphatase levels in PBC patients. Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Genfit's pipeline includes VS-01 for acute-on-chronic liver failure and GNS561 for cholangiocarcinoma. Given Iqirvo's competitive challenges and speculative pipeline, Genfit's long-term prospects remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Genfit GAAP EPS of -€0.21, revenue of €12.19M

Genfit press release (NASDAQ:GNFT): 1H GAAP EPS of -€0.21. Revenue of €12.19M (+255.4% Y/Y). Shares +3.27%.
Seeking Alpha • Sep 19

Genfit to acquire Swiss-based Versantis focused on liver diseases

Genfit (NASDAQ:GNFT) on Monday announced that it has signed an exclusivity agreement to acquire a private Swiss-based clinical stage biotechnology firm- Versantis - at an initial consideration of CHF 40M. Headquartered in Zurich, Switzerland, Versantis is focused on drug and diagnostic product development for the acute-on-chronic liver failure (ACLF) and other unmet medical needs in liver diseases. Its main asset, VS-01, is claimed as first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development for the timely recovery of ACLF and UCD. If approved, it would be the first drug to use the intraperitoneal route to simultaneously support the liver, kidney and brain, the organs that most often fail in cirrhotic patients. Consideration: This acquisition deal comprises of initial CHF 40M due at closing and consideration of up to CHF 65M upon positive Phase 2 results for VS-01 and VS-02 and regulatory approval of VS-01. Also, Versantis is eligible to receive 1/3 of the net proceeds resulting from the potential sale of the pediatric review voucher of VS-01.  Pascal Prigent, Chief Executive Officer of GENFIT, commented: “Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs.”
Seeking Alpha • Sep 07

Genfit S.A.: A 'Sum Of The Parts' Story

Summary Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward. An investment analysis follows in the paragraphs below. How can you govern a country which has 246 varieties of cheese?"― Charles de Gaulle We last posted a piece on small biotech outfit Genfit S.A. (GNFT) in March of 2021. We concluded saying the company has some interesting attributes, but it was probably too early to take a stake in its pending further development. The stock trades almost exactly where it did 18 months ago. No one else on Seeking Alpha has covered the company since then. Therefore, we will circle back on this name today. Seeking Alpha Company Overview: This France-based clinical stage biotech concern is focused on developing treatments primarily to treat disease of the liver and from gastroenterology. The shares currently trade just above four bucks a share and sports a market capitalization just north of $200 million. April Company Presentation Genfit is developing several compounds within its pipeline. Elafibranor, a dual agonist of PPARα and PPARδ, has shown encouraging results in mid-stage studies evaluating it to treat Primary Biliary Cholangitis or PBC. Elafibranor has Breakthrough Therapy and Orphan Drug status for PBC it should be noted. In late 2021, the company announced that it entered into an arrangement with Ipsen that will give that drug maker exclusive worldwide license to develop, manufacture and commercialize Elafibranor. April Company Presentation Genfit received a €120 million upfront payment for this license agreement and also can garner milestone payments up to €360 million (roughly 50% of this is for developmental milestones), plus tiered double-digit royalties of up to 20% on any commercialized sales. €80 million of the upfront payment was recognized as revenue in 2021, and €40 million was booked as deferred revenue and will be recognized as revenue in subsequent years following the completion of the ELATIVE double-blind study. Top-line results from that Phase 3 study evaluating Elafibranor to treat PBC should be out in the second quarter of next year. April Company Presentation The company is also working on a simple non-invasive test with Labcorp to identify at risk patients for NASH. This will be important if/when a drug is eventually approved for NASH. The company already has a significant database of patients from the work it did with its own NASH development which ended with the failure of the RESOLVE-IT trial in 2020. More data will be added with Ipsen's work on PBC. April Company Presentation The company is also working with other NASH development trials to ensure they knew steroids in their clinical trials, so that they can generate data with it. They also would naturally allow clients to use this test built on Genfit's NIS4 technology out of five blood based biomarker panels called NASHNext. That will launch from Labcorp if it is eventually approved. Genfit has an exclusive license agreement with LabCorp around this test. Genfit hopes this becomes the standard to identify at-risk NASH patients, provided a drug or drugs is approved for this widespread affliction. April Company Presentation The company also has two Phase 1 studies evaluating a candidate called NTZ, which they identified through phenotypic screening. The first Phase 1 study is focused on hepatic impairment, results from that study should be out shortly. The other Phase 1 study is focused on renal impairment. Data for this trial expected to be available in the fourth quarter of 2022. April Company Presentation Finally, late last year Genfit licensed an investigational compound from Genoscience Pharma called GNS5611. Genfit hopes to launch a Phase 1b/2 study towards the end of this year to evaluate this candidate for treating Cholangiocarcinoma (Bile Duct Cancer) which could be eligible for Orphan Drug status. Study data from this trial should be out in the first half of 2024.

CEO Tazminat Analizi

M. Prigent'un ücretlendirmesi Genfit'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2025n/an/a

-€39m

Mar 31 2025n/an/a

-€19m

Dec 31 2024€682k€406k

€2m

Sep 30 2024n/an/a

€12m

Jun 30 2024n/an/a

€22m

Mar 31 2024n/an/a

-€3m

Dec 31 2023€664k€394k

-€29m

Sep 30 2023n/an/a

-€32m

Jun 30 2023n/an/a

-€34m

Mar 31 2023n/an/a

-€29m

Dec 31 2022€632k€375k

-€24m

Sep 30 2022n/an/a

€12m

Jun 30 2022n/an/a

€48m

Mar 31 2022n/an/a

€58m

Dec 31 2021€562k€325k

€67m

Sep 30 2021n/an/a

€14m

Jun 30 2021n/an/a

-€39m

Mar 31 2021n/an/a

-€70m

Dec 31 2020€455k€325k

-€101m

Sep 30 2020n/an/a

-€84m

Jun 30 2020n/an/a

-€67m

Mar 31 2020n/an/a

-€66m

Dec 31 2019€325k€95k

-€65m

Tazminat ve Piyasa: M. 'nin toplam tazminatı ($USD 792.04K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.64M ).

Tazminat ve Kazançlar: M. şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

M. Prigent (57 yo)

6.5yrs
Görev süresi
€681,945
Tazminat

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Jean-Francois Mouney
Co-Founder & Chairman of the Board8.8yrs€382.68k0.094%
$ 506.5k
M. Prigent
Chief Executive Officer6.5yrs€681.95k0.062%
$ 333.8k
Bart Staels
Co-Founder & Chairman of the Scientific Advisory Boardno dataVeri yokVeri yok
Thomas Baetz
Chief Financial Officer4.9yrsVeri yokVeri yok
Pascal Caisey
Chief Operating Officer4yrsVeri yok0.0030%
$ 16.3k
Sakina Sayah-Jeanne
Chief Scientific Officerless than a yearVeri yokVeri yok
Jean-Christophe Marcoux
Chief Corporate Affairs Officer3yrsVeri yok0.0094%
$ 50.8k
Laurent Lannoo
Corporate Secretary & Director of Legal Affairs18.2yrsVeri yok0.023%
$ 122.1k
Stefanie Magner
Chief Compliance Officer & Executive VP of International Legal Affairs5yrsVeri yok0.0055%
$ 30.0k
Emilie Desodt
Executive Vice President of Human Resources4yrsVeri yok0.00047%
$ 2.5k
John Brozek
Executive Vice President of Data & Information Technology3yrsVeri yok0.0060%
$ 32.7k
Tom Huijbers
Executive Vice President of Regulatory3yrsVeri yokVeri yok
4.0yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş

Deneyimli Yönetim: GNFT.Y 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Jean-Francois Mouney
Co-Founder & Chairman of the Board8.8yrs€382.68k0.094%
$ 506.5k
Bart Staels
Co-Founder & Chairman of the Scientific Advisory Boardno dataVeri yokVeri yok
Philippe Moons
Board Observer5.1yrs€14.17k0.0021%
$ 11.3k
Florence Séjourné
Director8.8yrsVeri yokVeri yok
Scott L. Friedman
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Arun Sanyal
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Michael Trauner
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Catherine Larue
Independent Director8.8yrs€50.14kVeri yok
Vlad Ratziu
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Anne-Helene Monsellato
Independent Director8.8yrs€45.78kVeri yok
Katherine Kalin
Independent Director5.7yrs€38.39k0.010%
$ 54.3k
Eric Baclet
Independent Vice-Chairman of the Board5.7yrs€68.42k0.0024%
$ 13.0k
8.8yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: GNFT.Y 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/03/11 18:13
Gün Sonu Hisse Fiyatı2026/03/09 00:00
Kazançlar2025/06/30
Yıllık Kazançlar2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Genfit S.A. 14 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Geoffrey MeachamBofA Global Research
Arnaud CadartCIC Market Solutions (ESN)
Alethia YoungDeutsche Bank